In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Archimedes Pharma Ltd.

Latest From Archimedes Pharma Ltd.

Inivata Appoints Chair

Inivata Ltd., a cancer genomics company, has appointed Jeffrey Buchalter non-executive director and chair of its board. Most recently, Buchalter was CEO of Archimedes Pharma Ltd. and also received an award from the American Cancer Society for his commitment to cancer control and involvement in the oncology field. Buchalter has also been collaborating partner in the President's National Dialogue on Cancer and acted as chair of the board at National Childhood Cancer Foundation in the US.

Cancer Companies

Pharmalink readies for PhIII on 'astonishing' glomerulonephritis data

Pharmalink of Sweden is basking in the "astonishingly good" Phase IIb data of Nefecon, its oral modified-release capsule of budesonide, in the treatment of primary IgA nephropathy – the most common form of glomerulonephritis. The NEFIGEN trial met its primary endpoint at a planned interim analysis and has been stopped early with respect to statistical analysis of the endpoint.

Gynecology & Urology Orthopedics

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device

Kyowa Hakko Kirin expands European presence as ProStrakan acquires Archimedes

Kyowa Hakko Kirin, via its subsidiary ProStrakan, is acquiring the UK's Archimedes Pharma for £230m ($393m) in a move that will significantly expand ProStrakan's reach across Europe.

Gastrointestinal Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Nasal
      • Site Specific
  • Other Names / Subsidiaries
    • Archimedes Development Limited (ADL)